Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
accretion, acute, Affimed, altogether, AML, asset, automatic, Bipartisan, broadly, Budget, Children, classification, compensatory, congressional, CytomX, deficit, denintuzumab, diminished, duly, eighteen, enable, encompassing, encouraging, enfortumab, framework, gastrointestinal, herewith, hypomethylating, imply, inadequacy, inadequately, induction, Joint, Karyopharm, leukemia, light, mafodotin, MEI, Mersana, myelodysplastic, myeloid, occasion, older, oversee, passage, payor, Pembrolizumab, preclude, reclassified, recommend, recover, relationship, Relief, scrutinize, Select, simplify, simpson, summary, Sunshine, syndrome, talirine, Taxpayer, thereunto, todd, train, trillion, unavailability, undersigned, untreated, vadastuximab, venetoclax
Removed:
abuse, ABVD, added, affiliate, Arizona, arm, asterisk, attached, auristatin, begun, bleomycin, capitalizing, commenced, concomitant, consumed, contraindication, convert, disrupting, environment, exceed, experimental, Folotyn, fourteen, inherent, Istodax, larger, lawsuit, marked, microtubule, MMAE, monomethyl, OBT, organization, Oxford, peripheral, placebo, programmed, randomized, refractory, refuse, safely, satisfy, Spectrum, timeline, ultimate, wrong
Filing tables
Filing exhibits
Related press release
SGEN similar filings
Filing view
External links